GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Intelligent Bio Solutions INBS · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.29

+16.24%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Intelligent Bio Solutions

From its filings with the US Securities and Exchange Commission

SEC filings

Intelligent Bio Solutions is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INBS. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 30 June 2026, it reported revenue of $4.2m and a net loss of $12.4m. At that date it held total assets of $11.9m and shareholders' equity of $5.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
23 Dec 2020
Employees
51
Website
gbs.inc ↗
Head office
135 W 41ST ST,, NEW YORK, NY, 10036
Incorporated in
DE
Classification
Surgical & Medical Instruments & Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Steven BoyagesNon-Executive Independent Chairman of the Board, since 2020$45,000
  • Mr. Harry SimeonidisPresident, Chief Executive Officer, since 2017$393,220
  • Mr. Spiro SakirisChief Financial Officer$289,809
  • Ms. Nicola FraserIndependent Director$3,667
  • Mr. Jonathan HurdIndependent Director$35,000
  • Mr. Jason IsenbergIndependent Director$33,750
  • Mr. Valter PintoManaging Director, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing non-invasive real-time diagnostic tests for diabetic patients in the Health Care sector.
  • Operating two segments: Commercially available Intelligent Fingerprinting Products and Development Stage Saliva Glucose Biosensor Platform.
  • Portable drug screening system using fingerprint sweat analysis with one-time cartridges and handheld readers.

Weaknesses

  • 51 full-time employees limit scalability and R&D capacity in the Health Care industry.
  • IPO listing date 23 December 2020 restricts recent market performance evaluation.
  • Commercially available products face competition in the diagnostic technology market.

Opportunities

  • Expanding Saliva Glucose Biosensor Platform to replace invasive blood glucose monitoring for diabetic patients.
  • Growing demand for non-invasive diagnostic tests in the Health Care sector.
  • Developing Point of Care diagnostic tests in clinical chemistry, immunology, and endocrinology modalities.

Threats

  • Competition from established diagnostic technology firms in the Health Care industry.
  • Regulatory challenges for new biosensor products in the US market.
  • Limited employee count of 51 may hinder rapid response to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.